ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 554

Are There Any Associations between ANA Development and Poor Treatment Response to Bdmards in RA Patients?

Yuki Ishikawa1, Motomu Hashimoto2, Hiromu Ito3, Masao Tanaka2, Naoichiro Yukawa4, Takao Fujii5, Wataru Yamamoto6, Tsuneyo Mimori7 and Chikashi Terao8,9,10, 1One Joslin Place, Joslin Diabetes Center, Harvard Medical School, Boston, MA, 2Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 3Department of Orthopedic Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 4Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Wakayama University, Wakayama, Japan, 5Dept of Rheum/Clinical Immun, Wakayama Medical University, Wakayama, Japan, 6Department of Health Information Management, Kurashiki Sweet Hospital, Okayama, Japan, 7Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 8Center for Investigative Medical Sciences, RIKEN, Yokohama, Japan, 9Clinical Research Center, Shizuoka General Hospital, Shizuoka, Japan, 10Department of Applied Genetics, The School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: ANA, anti-TNF therapy, autoantibodies and rheumatoid arthritis (RA), Biologic agents

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Rheumatoid Arthritis – Treatments Poster I: Strategy and Epidemiology

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: It has been well known that anti-TNF-α treatment for RA patients is associated with ANA development. We previously reported that ANA development along with ANA levels at base line were associated with poor outcomes of infliximab (IFX)(1). However, no replication studies have been reported. In addition, whether the findings are true to general biologic DMARDs (bDMARDs) is uncertain. Here, we evaluate an association between poor treatment response and ANA development during bDMARDs treatment in RA patients and analyze correlates of ANA development.

Methods: Japanese RA patients treated with (n=657) or without (n=211) bDMARDs (IFX, etanercept ETN, adalimumab ADA, golimumab GLM, certolizumab pegol CZP, tocilizumab TCZ, abatacept ABT) as a first line bDMARD were enrolled from a single center cohort. The study participants were not registered in the previous study (1). ANA was measured by indirect immunofluorescence assays at multiple time points of treatment. We conducted multiple logistic linear regression analysis to assess effects of ANA development on treatment outcomes. We further analyzed correlates of ANA development by using patients with RA who were treated by MTX but not by bDMARDs as controls.

Results: ANA development (≥ 2 times baseline levels) at 3 months and at 6-12 months after bDMARDs initiation were significantly associated with insufficient response within a year (odds ratio (OR)=3.51, p=0.020) and between 12 and 24 months (OR=3.16, p=0.038), respectively. The associations remained significant after conditioning on each bDMARD use (OR=3.16-3.56, p<0.05), indicating the observed association was not limited to IFX use.

The use of IFX was a risk for ANA development (OR=6.36, p<0.001), and the use of other TNF-α inhibitors (TNFi) also showed the same tends as IFX use (OR=1.68, p=0.214). On the other hand, the use of non-TNFi bDMARDs was not associated with ANA development (OR=0.792, p=0.675).

Conclusion: ANA development could be a marker of poor treatment response in RA patients undergoing bDMARDs treatment. Undefined common factors among RA patients treated with bDMARDs might influence ANA development and subsequent poor treatment outcome.

Reference:

1. Yukawa N, Fujii T, Kondo-Ishikawa S, Yoshifuji H, Kawabata D, Nojima T, et al. Correlation of antinuclear antibody and anti-double-stranded DNA antibody with clinical response to infliximab in patients with rheumatoid arthritis: a retrospective clinical study. Arthritis Res Ther. 2011;13(6):R213.


Disclosure: Y. Ishikawa, None; M. Hashimoto, None; H. Ito, None; M. Tanaka, None; N. Yukawa, None; T. Fujii, None; W. Yamamoto, None; T. Mimori, None; C. Terao, None.

To cite this abstract in AMA style:

Ishikawa Y, Hashimoto M, Ito H, Tanaka M, Yukawa N, Fujii T, Yamamoto W, Mimori T, Terao C. Are There Any Associations between ANA Development and Poor Treatment Response to Bdmards in RA Patients? [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/are-there-any-associations-between-ana-development-and-poor-treatment-response-to-bdmards-in-ra-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/are-there-any-associations-between-ana-development-and-poor-treatment-response-to-bdmards-in-ra-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology